Table 2.
Effects of theophylline (50 mg/kg bw) on soleus muscle and heart mRNA content of the different proteolytic systems in rats bearing the Yoshida AH-130 ascites hepatoma
| |
|
SOLEUS |
|
|
|
|
HEART |
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Treatment |
C(n = 5) |
T(n = 5) |
T + TPH(n = 6) |
ANOVA |
C(n = 5) |
T(n = 5) |
T + TPH(n = 6) |
ANOVA |
||
| A | B | A | B | |||||||
|
PROTEOLYTIC SYSTEM | ||||||||||
|
Ubiquitin-dependent | ||||||||||
| Ubiquitin |
100 ± 6 |
204 ± 15 |
118 ± 18 |
0,000 |
0,001 |
100 ± 5 |
302 ± 51 |
177 ± 32 |
0,001 |
0,019 |
| Proteasome subunit C2 |
100 ± 13 |
168 ± 10 |
160 ± 40 |
ns |
ns |
100 ± 3 |
303 ± 47 |
191 ± 23 |
0,000 |
0,010 |
| Proteasome subunit C8 |
100 ± 5 |
111 ± 8 |
97 ± 25 |
ns |
ns |
100 ± 3 |
262 ± 26 |
164 ± 22 |
0,000 |
0,005 |
| E2 |
100 ± 5 |
527 ± 129 |
288 ± 80 |
0,004 |
0,063 |
100 ± 5 |
224 ± 55 |
114 ± 19 |
0,013 |
0,025 |
| MuRF-1 |
100 ± 3 |
171 ± 19 |
80 ± 26 |
0,025 |
0,007 |
100 ± 3 |
309 ± 92 |
177 ± 38 |
0,015 |
ns |
| Atrogin-1 |
100 ± 8 |
392 ± 22 |
362 ± 71 |
0,002 |
ns |
100 ± 3 |
161 ± 21 |
152 ± 21 |
0,039 |
ns |
|
Calcium-dependent | ||||||||||
| m-calpain |
100 ± 4 |
117 ± 23 |
142 ± 43 |
ns |
ns |
100 ± 4 |
307 ± 58 |
170 ± 18 |
0,001 |
0,009 |
|
Lysosomal | ||||||||||
| Cathepsin-B | 100 ± 4 | 111 ± 8 | 151 ± 34 | ns | ns | 100 ± 2 | 194 ± 40 | 111 ± 13 | 0,010 | ns |
For further details, see the Material and Methods section. The results are expressed as a percentage of controls (T). All data are mean ± SEM. C = non-tumour-bearing rats, T = tumour-bearing rats, T + TPH = tumour-bearing rats treated with theophylline. Statistical significance of the results by two-way analysis of variance (ANOVA) are indicated by: ns (non-significant differences), A (tumour effect), B (treatment effect).